Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Monday, October 16th. The stock was sold at an average price of $84.54, for a total transaction of $253,620.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Clovis Oncology, Inc. (CLVS) opened at 76.99 on Friday. Clovis Oncology, Inc. has a 12 month low of $25.81 and a 12 month high of $99.45. The firm has a 50 day moving average of $77.56 and a 200-day moving average of $72.03. The firm’s market cap is $3.76 billion.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by ($0.02). The company had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. During the same period last year, the business earned ($2.07) EPS. The firm’s revenue for the quarter was down 32.5% on a year-over-year basis. On average, equities research analysts forecast that Clovis Oncology, Inc. will post ($7.58) earnings per share for the current year.
WARNING: “Gillian C. Ivers-Read Sells 3,000 Shares of Clovis Oncology, Inc. (CLVS) Stock” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/28/gillian-c-ivers-read-sells-3000-shares-of-clovis-oncology-inc-clvs-stock.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Phocas Financial Corp. acquired a new stake in shares of Clovis Oncology in the second quarter valued at about $112,000. Advisors Asset Management Inc. lifted its stake in shares of Clovis Oncology by 160.7% in the second quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,168 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 100 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Clovis Oncology in the first quarter valued at about $204,000. Finally, Legato Capital Management LLC acquired a new stake in shares of Clovis Oncology in the second quarter valued at about $220,000. Hedge funds and other institutional investors own 99.08% of the company’s stock.
Several research firms have recently commented on CLVS. Cann reiterated a “hold” rating on shares of Clovis Oncology in a research note on Monday, July 31st. Zacks Investment Research downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Gabelli initiated coverage on shares of Clovis Oncology in a research report on Friday, July 7th. They set a “buy” rating and a $125.00 target price for the company. J P Morgan Chase & Co restated an “overweight” rating on shares of Clovis Oncology in a research report on Tuesday, August 1st. Finally, Vetr upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $87.50 target price for the company in a research report on Wednesday, July 19th. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $87.56.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.